Basis for the use of rhDNase as a therapy in cystic fibrosis

Rodney Pearlman, Steven Shire, David Cipolla, Ann Daugherty, Tom Patapoff, Ross Clark, Gilbert Keller, Randy Mrsny

Research output: Chapter or section in a book/report/conference proceedingChapter in a published conference proceeding

Abstract

To gauge the effect of nebulization on rhDNase, a clinical formulation of the protein was nebulized and samples were collected and analyzed by a number of analytical methods. Characterization of the aerodynamic profile of the aerosol was also performed. The ability of rhDNase as a therapeutic agent for the treatment of CF is dependent on its ability to hydrolyze the excessive amounts of DNA contained in the sputum of CF patients. The paper shows that hydrolysis of DNA leads to a drastic reduction in the viscoelastic properties of CF sputum. This reduction should, in turn, permit easier clearance of the airways, thus aiding the patient's ability to breathe. rhDNase was shown to be fully active after nebulization and its mode of action in reducing the viscoelastic properties of CF sputum was described.

Original languageEnglish
Title of host publicationPolymeric Materials Science and Engineering, Proceedings of the ACS Division of Polymeric Materials Science and Engineering
PublisherPubl by ACS
Pages222-223
Number of pages2
ISBN (Print)0841222169
Publication statusPublished - 31 Dec 1992

Publication series

NamePolymeric Materials Science and Engineering, Proceedings of the ACS Division of Polymeric Materials Science and Engineering
Volume66
ISSN (Print)0743-0515

ASJC Scopus subject areas

  • Chemical Engineering (miscellaneous)
  • Polymers and Plastics

Fingerprint

Dive into the research topics of 'Basis for the use of rhDNase as a therapy in cystic fibrosis'. Together they form a unique fingerprint.

Cite this